Pacer Advisors
BHVN

Pacer Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Pacer Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-957
Closed -$65K – 1623
2021
Q1 		$65K Sell
957
-548
-36% -$44.3K ﹤0.01% 1404
2020
Q4 		$129K Buy
+1,505
New +$128K ﹤0.01% 1320

Other funds holding BHVN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Pacer Advisors's BHVN Position: Q2 2021 in Review

Pacer Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2021, closing a stake of 957 shares — an estimated $65K sold.

Pacer Advisors first reported a position in BHVN in Q4 2020 and held it in 2 quarters. The position peaked at $129K in Q4 2020. 223 funds tracked by Wall St. Rank hold BHVN as of Q2 2021.

  • Pacer Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2021 after selling out during the quarter.
  • Pacer Advisors sold 957 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2021, an estimated $65K.
  • Pacer Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2020 and held it in 2 quarters.
  • Pacer Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $129K in Q4 2020.
  • 223 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.